| 22 0.11 (0.5%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34 | 1-year : | 39.67 |
| Resists | First : | 29.11 | Second : | 33.97 |
| Pivot price | 25.23  |
|||
| Supports | First : | 21.26 | Second : | 17.68 |
| MAs | MA(5) : | 22.74 |
MA(20) : | 26.14 |
| MA(100) : | 32.68 |
MA(250) : | 31.45 |
|
| MACD | MACD : | -2.3 |
Signal : | -2 |
| %K %D | K(14,3) : | 7 |
D(3) : | 8.7 |
| RSI | RSI(14): 23.9 |
|||
| 52-week | High : | 44.34 | Low : | 21.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ZLAB ] has closed above bottom band by 11.4%. Bollinger Bands are 30.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.42 - 22.57 | 22.57 - 22.7 |
| Low: | 21.43 - 21.62 | 21.62 - 21.79 |
| Close: | 21.71 - 22.01 | 22.01 - 22.27 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Tue, 11 Nov 2025
Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) - Seeking Alpha
Sun, 09 Nov 2025
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
Sun, 09 Nov 2025
Zai Lab Limited (NASDAQ:ZLAB) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 07 Nov 2025
Zai Lab Ltd’s Earnings Call: Mixed Outlook Amid Growth and Challenges - TipRanks
Fri, 07 Nov 2025
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB) - simplywall.st
Fri, 07 Nov 2025
What Does The Future Hold For Zai Lab Limited (NASDAQ:ZLAB)? These Analysts Have Been Cutting Their Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 111 (M) |
| Shares Float | 1,080 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 42.6 (%) |
| Shares Short | 4,810 (K) |
| Shares Short P.Month | 4,880 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.19 |
| Profit Margin | -49.7 % |
| Operating Margin | -50 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 9.3 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 3.84 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -175 (M) |
| Levered Free Cash Flow | -217 (M) |
| PE Ratio | -11 |
| PEG Ratio | 0 |
| Price to Book value | 3.05 |
| Price to Sales | 5.72 |
| Price to Cash Flow | -13.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|